United States: Supreme Court Construes Key Provisions Of Biosimilar Statute

On June 12, 2017, the United States Supreme Court issued a unanimous opinion, written by Justice Thomas, in Sandoz, Inc. v. Amgen, Inc.,1 marking the High Court's first decision construing the Biologics Price Competition and Innovation Act of 2009 (the BPCIA). The BPCIA, codified under 42 U.S.C. § 262, governs the approval of a "biosimilar" version of a previously licensed biologic product (a reference product) of a manufacturer (a reference product sponsor). The BPCIA sets forth a complex scheme for the exchange of product and patent information between the biosimilar applicant and the reference product sponsor which is intended to provide a pathway to resolve patent disputes, including through patent litigation.

The Court addressed two key provisions under the BPCIA. The first provision, § 262 (l)(2)(A), provides that a biosimilar applicant "shall provide" to the reference product sponsor its biosimilar application and its manufacturing information within 20 days after the Food and Drug Administration (FDA) accepts the application. On this issue, the Supreme Court held that the provision is not enforceable by injunctive relief under federal law, but remanded for a determination as to whether injunctive relief is available under state law. The second provision, § 262 (l)(8)(A), provides that a biosimilar applicant "shall provide" to the reference product sponsor notice at least 180 days "before the date of the first commercial marketing of the biological product licensed under subsection (k) [the subsection directed to biosimilar applications]." On this issue, the Supreme Court held that a biosimilar applicant may provide notice of commercial marketing before FDA approval of the biosimilar application.

In the case, Sandoz had filed an application with the FDA for approval to market a biosimilar of Amgen's reference product, Neulasta® (filgrastim), under the brand name Zarxio®. Although Sandoz had notified Amgen of the filing of its biosimilar application, it declined to provide its application and manufacturing information under § 262 (l)(2)(A) and informed Amgen that it intended to market its biosimilar product immediately upon receiving FDA approval. Sandoz further informed Amgen that Amgen could sue for patent infringement immediately under § 262 (l)(9)(C), which provides that a reference product sponsor can bring a declaratory judgment action against a biosimilar applicant which "fails to provide the application and information required under paragraph (2)(A)."

Amgen sued Sandoz in the United States District Court for the Northern District of California for patent infringement and also asserted two claims under California state unfair competition law. Amgen alleged that Sandoz engaged in "unlawful" conduct when it failed to provide its biosimilar application and manufacturing information under § 262 (l)(2)(A), and also when it provided its notice of commercial marketing under § 262 (l)(8)(A) before, rather than after, its biosimilar application was approved by the FDA. Amgen sought injunctive relief to enforce both provisions of the BPCIA that it accused Sandoz of violating. Sandoz counterclaimed for declaratory judgment that the asserted patent was invalid and not infringed, and that it had not violated the BPCIA.

The District Court granted Sandoz partial summary judgment on the BPCIA claims and dismissed Amgen's state law unfair competition claims. Thereafter, a divided Court of Appeals for the Federal Circuit2 held that an injunction under federal law was not available to enforce § 262 (l)(2)(A) where the biosimilar applicant does not provide the reference product sponsor with its biosimilar application or manufacturing information, but that the 180-day notice of commercial marketing under § 262 (l)(8)(A) could not be provided until after the biosimilar application is approved and that the provision could be enforced by injunctive relief.

After the FDA licensed Sandoz's biosimilar application while the action was pending, Sandoz gave Amgen a second notice of commercial marketing. The Federal Circuit enjoined Sandoz from marketing its approved biosimilar product until 180 days after it provided its second notice of commercial marketing.

The Supreme Court granted certiorari, heard oral argument on April 26, 2017, and issued its unanimous opinion on June 12, 2017.

The Supreme Court affirmed the Federal Circuit's decision that § 262 (l)(2)(A)'s requirement that the biosimilar applicant provide its biosimilar application and manufacturing information was not enforceable under federal law by injunctive relief. In reaching this decision, the Supreme Court concluded that § 262 (l)(9)(C) authorizes the reference product sponsor to bring an immediate declaratory judgment action when the biosimilar applicant fails to provide the required information3 and that "[t]he remedy provided by § 262 (l)(9)(C) excludes all other federal remedies, including injunctive relief."4 However, the Supreme Court remanded the issue of whether injunctive relief was available under state law. The Supreme Court reasoned that whether the disclosure requirement of § 262 (l)(2)(A) is mandatory or conditional is an issue of state law, and if mandatory, a violation of the provision could be "unlawful" under state law. The Supreme Court further stated that if on remand the Federal Circuit determines that noncompliance with § 262 (l)(2)(A) is unlawful under California law, the Federal Circuit should proceed to determine whether the BPCIA preempts any additional remedy available under state law. The Supreme Court added that the Federal Circuit "is also of course free to address the pre-emption question first by assuming that a remedy under state law exists."5

In reversing the Federal Circuit's decision that § 262 (l)(8)(A)'s 180-day notice of commercial manufacturing could only be provided after the FDA approved the biosimilar application, the Supreme Court rejected the Federal Circuit's construction based on the use of the term "licensed" in the provision. Whereas the Federal Circuit had concluded that the term "licensed" meant that the FDA had to have licensed the biosimilar product before the 180-day notice under § 262 (l)(8)(A) could be given, the Supreme Court concluded that "[t]he statute's use of the word 'licensed' merely reflects the fact that, on the 'date of the first commercial marketing,' the product must be licensed."6 The Supreme Court therefore held that Sandoz had "fully complied with § 262 (l)(8)(A) when it first gave notice (before licensure)" and that "the Federal Circuit erred in issuing a federal injunction prohibiting Sandoz from marketing Zarxio until 180 days after licensure."7 Furthermore, because Amgen's state law claims were predicated on its argument that the BPCIA forbid prelicensure notice, the state law claims also failed.

Justice Breyer, in a concurring opinion, stated that "Congress implicitly delegated to the Food and Drug Administration authority to interpret [the] same terms" that the Supreme Court interpreted in its opinion, and set forth his understanding that the FDA "may well have the authority to depart from, or to modify, today's interpretation" of the BPCIA.8

Footnotes

1. 582 U.S. ___ (June 12, 2017), No. 15-1039.

2. Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015). The majority opinion of the Federal Circuit was written by Judge Lourie. Judges Newman and Chen concurred-in-part and dissented-in-part on different aspects of the majority opinion.

3. The Supreme Court disagreed with the Federal Circuit's alternative holding that 35 U.S.C. § 271(e)(2)(C)(ii) precluded enforcing § 262 (l)(2)(A) by federal injunction. The Supreme Court noted that § 271(e)(2)(C)(ii), which made the filing of a biosimilar application an act of patent infringement, did not also make an act of infringement, as the Federal Circuit had concluded, the failure to provide the biosimilar application and manufacturing information. Accordingly, the Supreme Court concluded that only § 262 (l)(9)(C), and not § 271(e)(2)(C)(ii), provided a remedy for a biosimilar applicant failing to provide its application and manufacturing information. Sandoz, slip op. at 11-12.

4. Id. at 12. In a footnote, the Supreme Court stated that "we express no view on whether a district court could take into account an applicant's violation of § 262 (l)(2)(A) (or any other BPCIA procedural requirement) in deciding whether to grant a preliminary injunction under 35 U.S.C. § 271 (e)(4)(B) or § 283 against marketing the biosimilar," citing case authority on a court's consideration of the "balance of equities" in deciding whether to grant a preliminary injunction. Id. at 13 n.2.

5. Id. at 15.

6. Id. at 16. The Supreme Court noted that § 262 (l)(8)(A) had only one timing requirement (that the biosimilar applicant had to provide notice at least 180 days prior to commercial marketing), whereas the Federal Circuit had interpreted the provision as having two timing requirements (the biosimilar applicant must provide notice after licensing and at least 180 days before commercial marketing). The Supreme Court pointed to another to another provision, § 262 (l)(8)(B), which did have two timing requirements as support for its interpretation that Congress only intended a single timing requirement for § 262 (l)(8)(A).

7. Id. at 16.

8. Id. at 1 (Breyer, J. concurring).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions